 | • レポートコード：20QY06-06896 • 出版社/出版日：QYResearch / 2020年6月3日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、143ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、生物製剤及びバイオシミラーのグローバル市場について種類別（モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他）、用途別（腫瘍、糖尿病、循環器、血友病、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・生物製剤及びバイオシミラー市場の概要 ・世界の主要地域別生物製剤及びバイオシミラー市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の生物製剤及びバイオシミラー市場規模2015-2026：種類別（モノクローナル抗体、インターフェロン、エリスロポエチン、インスリン、ワクチン、その他） ・世界の生物製剤及びバイオシミラー市場規模2015-2026：用途別（腫瘍、糖尿病、循環器、血友病、その他） ・生物製剤及びバイオシミラーの北米市場規模2015-2020 ・生物製剤及びバイオシミラーのヨーロッパ市場規模2015-2020 ・生物製剤及びバイオシミラーの中国市場規模2015-2020 ・生物製剤及びバイオシミラーの日本市場規模2015-2020 ・生物製剤及びバイオシミラーの東南アジア市場規模2015-2020 ・生物製剤及びバイオシミラーのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Roche、、Amgen、、AbbVie、、Sanofi-Aventis、、Johnson & Johnson、、Pfizer、、Novo Nordisk、、Eli Lilly、、Novartis、、Merck、、3sbio、、Changchun High Tech、、CP Guojian、、Biotech、、Gelgen、、Innovent、、Dong Bao、、Ganlee、） ・生物製剤及びバイオシミラーの製造コスト分析 ・販売チャネル、流通業者、顧客 ・生物製剤及びバイオシミラーの市場動向・機会・課題 ・調査の結論 |
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
Most of biologics manufacturer are concentrated in US, Germany,UK and other developed countries. But in biosimilars industry the situation is different, manufacturer in developing countries play a very important role.
Through the research we tend to believe that the growth of biologics industry maybe slow but high profits during the period of patent may attractive. As to biosimilars, now is a changce for newcomers and they will greatly change the industry.
Market Analysis and Insights: Global Biologics and Biosimilars Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biologics and Biosimilars market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Biologics and Biosimilars industry.
Based on our recent survey, we have several different scenarios about the Biologics and Biosimilars YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 229600 million in 2019. The market size of Biologics and Biosimilars will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
Global Biologics and Biosimilars Scope and Market Size
The global Biologics and Biosimilars market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biologics and Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Biologics and Biosimilars market is segmented into
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application, the Biologics and Biosimilars market is segmented into
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
The Biologics and Biosimilars market is analysed and market size information is provided by regions (countries). Segment by Application, the Biologics and Biosimilars market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Biologics and Biosimilars Market Share Analysis
Biologics and Biosimilars market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Biologics and Biosimilars business, the date to enter into the Biologics and Biosimilars market, Biologics and Biosimilars product introduction, recent developments, etc.
The major vendors covered:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
レポート目次1 Biologics and Biosimilars Market Overview
1.1 Biologics and Biosimilars Product Scope
1.2 Biologics and Biosimilars Segment by Type
1.2.1 Global Biologics and Biosimilars Sales by Type (2020-2026)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 Biologics and Biosimilars Segment by Application
1.3.1 Global Biologics and Biosimilars Sales Comparison by Application (2020-2026)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Biologics and Biosimilars Market Estimates and Forecasts (2015-2026)
1.4.1 Global Biologics and Biosimilars Sales Growth Rate (2015-2026)
1.4.2 Global Biologics and Biosimilars Revenue and Growth Rate (2015-2026)
1.4.3 Global Biologics and Biosimilars Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Biologics and Biosimilars Industry Impact
1.5.1 How the Covid-19 is Affecting the Biologics and Biosimilars Industry
1.5.1.1 Biologics and Biosimilars Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Biologics and Biosimilars Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Biologics and Biosimilars Players to Combat Covid-19 Impact
2 Biologics and Biosimilars Estimate and Forecast by Region
2.1 Global Biologics and Biosimilars Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Biologics and Biosimilars Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Biologics and Biosimilars Sales Market Share by Region (2015-2020)
2.2.2 Global Biologics and Biosimilars Revenue Market Share by Region (2015-2020)
2.3 Global Biologics and Biosimilars Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Biologics and Biosimilars Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Biologics and Biosimilars Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Biologics and Biosimilars Estimates and Projections (2015-2026)
2.4.2 Europe Biologics and Biosimilars Estimates and Projections (2015-2026)
2.4.3 China Biologics and Biosimilars Estimates and Projections (2015-2026)
2.4.4 Japan Biologics and Biosimilars Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Biologics and Biosimilars Estimates and Projections (2015-2026)
2.4.6 India Biologics and Biosimilars Estimates and Projections (2015-2026)
3 Global Biologics and Biosimilars Competition Landscape by Players
3.1 Global Top Biologics and Biosimilars Players by Sales (2015-2020)
3.2 Global Top Biologics and Biosimilars Players by Revenue (2015-2020)
3.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biologics and Biosimilars as of 2019)
3.4 Global Biologics and Biosimilars Average Price by Company (2015-2020)
3.5 Manufacturers Biologics and Biosimilars Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Biologics and Biosimilars Players (Opinion Leaders)
4 Global Biologics and Biosimilars Market Size by Type
4.1 Global Biologics and Biosimilars Historic Market Review by Type (2015-2020)
4.1.1 Global Biologics and Biosimilars Sales Market Share by Type (2015-2020)
4.1.2 Global Biologics and Biosimilars Revenue Market Share by Type (2015-2020)
4.1.3 Global Biologics and Biosimilars Price by Type (2014-2020)
4.2 Global Biologics and Biosimilars Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Biologics and Biosimilars Sales Forecast by Type (2021-2026)
4.2.2 Global Biologics and Biosimilars Revenue Forecast by Type (2021-2026)
4.2.3 Global Biologics and Biosimilars Price Forecast by Type (2021-2026)
5 Global Biologics and Biosimilars Market Size by Application
5.1 Global Biologics and Biosimilars Historic Market Review by Application (2015-2020)
5.1.1 Global Biologics and Biosimilars Sales Market Share by Application (2015-2020)
5.1.2 Global Biologics and Biosimilars Revenue Market Share by Application (2015-2020)
5.1.3 Global Biologics and Biosimilars Price by Application (2015-2020)
5.2 Global Biologics and Biosimilars Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Biologics and Biosimilars Sales Forecast by Application (2021-2026)
5.2.2 Global Biologics and Biosimilars Revenue Forecast by Application (2021-2026)
5.2.3 Global Biologics and Biosimilars Price Forecast by Application (2021-2026)
3 North America Biologics and Biosimilars Market Facts & Figures
3.2 North America Biologics and Biosimilars Sales Market Share by Company (2015-2020)
3.3 North America Biologics and Biosimilars Sales Market Share by Type (2015-2020)
3.4 North America Biologics and Biosimilars Sales Market Share by Application (2015-2020)
4 Europe Biologics and Biosimilars Market Facts & Figures
4.2 Europe Biologics and Biosimilars Sales Market Share by Company (2015-2020)
4.3 Europe Biologics and Biosimilars Sales Market Share by Type (2015-2020)
4.4 Europe Biologics and Biosimilars Sales Market Share by Application (2015-2020)
5 China Biologics and Biosimilars Market Facts & Figures
5.2 China Biologics and Biosimilars Sales Market Share by Company (2015-2020)
5.3 China Biologics and Biosimilars Sales Market Share by Type (2015-2020)
5.4 China Biologics and Biosimilars Sales Market Share by Application (2015-2020)
6 Japan Biologics and Biosimilars Market Facts & Figures
6.2 Japan Biologics and Biosimilars Sales Market Share by Company (2015-2020)
6.3 Japan Biologics and Biosimilars Sales Market Share by Type (2015-2020)
6.4 Japan Biologics and Biosimilars Sales Market Share by Application (2015-2020)
7 Southeast Asia Biologics and Biosimilars Market Facts & Figures
7.2 Southeast Asia Biologics and Biosimilars Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Biologics and Biosimilars Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Biologics and Biosimilars Sales Market Share by Application (2015-2020)
8 India Biologics and Biosimilars Market Facts & Figures
8.2 India Biologics and Biosimilars Sales Market Share by Company (2015-2020)
8.3 India Biologics and Biosimilars Sales Market Share by Type (2015-2020)
8.4 India Biologics and Biosimilars Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Biologics and Biosimilars Business
12.1 Roche
12.1.1 Roche Biologics and Biosimilars Corporation Information
12.1.2 Roche Biologics and Biosimilars Business Overview and Total Revenue
12.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Roche Biologics and Biosimilars Products Offered
12.1.5 Roche Recent Development
12.2 Amgen
12.2.1 Amgen Biologics and Biosimilars Corporation Information
12.2.2 Amgen Biologics and Biosimilars Business Overview and Total Revenue
12.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Amgen Biologics and Biosimilars Products Offered
12.2.5 Amgen Recent Development
12.3 AbbVie
12.3.1 AbbVie Biologics and Biosimilars Corporation Information
12.3.2 AbbVie Biologics and Biosimilars Business Overview and Total Revenue
12.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.3.4 AbbVie Biologics and Biosimilars Products Offered
12.3.5 AbbVie Recent Development
12.4 Sanofi-Aventis
12.4.1 Sanofi-Aventis Biologics and Biosimilars Corporation Information
12.4.2 Sanofi-Aventis Biologics and Biosimilars Business Overview and Total Revenue
12.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Sanofi-Aventis Biologics and Biosimilars Products Offered
12.4.5 Sanofi-Aventis Recent Development
12.5 Johnson & Johnson
12.5.1 Johnson & Johnson Biologics and Biosimilars Corporation Information
12.5.2 Johnson & Johnson Biologics and Biosimilars Business Overview and Total Revenue
12.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Johnson & Johnson Biologics and Biosimilars Products Offered
12.5.5 Johnson & Johnson Recent Development
12.6 Pfizer
12.6.1 Pfizer Biologics and Biosimilars Corporation Information
12.6.2 Pfizer Biologics and Biosimilars Business Overview and Total Revenue
12.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Pfizer Biologics and Biosimilars Products Offered
12.6.5 Pfizer Recent Development
12.7 Novo Nordisk
12.7.1 Novo Nordisk Biologics and Biosimilars Corporation Information
12.7.2 Novo Nordisk Biologics and Biosimilars Business Overview and Total Revenue
12.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Novo Nordisk Biologics and Biosimilars Products Offered
12.7.5 Novo Nordisk Recent Development
12.8 Eli Lilly
12.8.1 Eli Lilly Biologics and Biosimilars Corporation Information
12.8.2 Eli Lilly Biologics and Biosimilars Business Overview and Total Revenue
12.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Eli Lilly Biologics and Biosimilars Products Offered
12.8.5 Eli Lilly Recent Development
12.9 Novartis
12.9.1 Novartis Biologics and Biosimilars Corporation Information
12.9.2 Novartis Biologics and Biosimilars Business Overview and Total Revenue
12.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Novartis Biologics and Biosimilars Products Offered
12.9.5 Novartis Recent Development
12.10 Merck
12.10.1 Merck Biologics and Biosimilars Corporation Information
12.10.2 Merck Biologics and Biosimilars Business Overview and Total Revenue
12.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Merck Biologics and Biosimilars Products Offered
12.10.5 Merck Recent Development
12.11 3sbio
12.11.1 3sbio Biologics and Biosimilars Corporation Information
12.11.2 3sbio Biologics and Biosimilars Business Overview and Total Revenue
12.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.11.4 3sbio Biologics and Biosimilars Products Offered
12.11.5 3sbio Recent Development
12.12 Changchun High Tech
12.12.1 Changchun High Tech Biologics and Biosimilars Corporation Information
12.12.2 Changchun High Tech Biologics and Biosimilars Business Overview and Total Revenue
12.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Changchun High Tech Biologics and Biosimilars Products Offered
12.12.5 Changchun High Tech Recent Development
12.13 CP Guojian
12.13.1 CP Guojian Biologics and Biosimilars Corporation Information
12.13.2 CP Guojian Biologics and Biosimilars Business Overview and Total Revenue
12.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.13.4 CP Guojian Biologics and Biosimilars Products Offered
12.13.5 CP Guojian Recent Development
12.14 Biotech
12.14.1 Biotech Biologics and Biosimilars Corporation Information
12.14.2 Biotech Biologics and Biosimilars Business Overview and Total Revenue
12.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Biotech Biologics and Biosimilars Products Offered
12.14.5 Biotech Recent Development
12.15 Gelgen
12.15.1 Gelgen Biologics and Biosimilars Corporation Information
12.15.2 Gelgen Biologics and Biosimilars Business Overview and Total Revenue
12.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Gelgen Biologics and Biosimilars Products Offered
12.15.5 Gelgen Recent Development
12.16 Innovent
12.16.1 Innovent Biologics and Biosimilars Corporation Information
12.16.2 Innovent Biologics and Biosimilars Business Overview and Total Revenue
12.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Innovent Biologics and Biosimilars Products Offered
12.16.5 Innovent Recent Development
12.17 Dong Bao
12.17.1 Dong Bao Biologics and Biosimilars Corporation Information
12.17.2 Dong Bao Biologics and Biosimilars Business Overview and Total Revenue
12.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Dong Bao Biologics and Biosimilars Products Offered
12.17.5 Dong Bao Recent Development
12.18 Ganlee
12.18.1 Ganlee Biologics and Biosimilars Corporation Information
12.18.2 Ganlee Biologics and Biosimilars Business Overview and Total Revenue
12.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Ganlee Biologics and Biosimilars Products Offered
12.18.5 Ganlee Recent Development
13 Biologics and Biosimilars Manufacturing Cost Analysis
13.1 Biologics and Biosimilars Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Biologics and Biosimilars
13.4 Biologics and Biosimilars Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Biologics and Biosimilars Distributors List
14.3 Biologics and Biosimilars Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
List of TablesTable 1. Global Biologics and Biosimilars Sales (K Units) Growth Rate by Type (2020-2026)
Table 2. Global Biologics and Biosimilars Sales (K Units) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Biologics and Biosimilars Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Biologics and Biosimilars Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Biologics and Biosimilars Players to Combat Covid-19 Impact
Table 8. Global Market Biologics and Biosimilars Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Biologics and Biosimilars Sales (K Units) by Region (2015-2020)
Table 10. Global Biologics and Biosimilars Sales Market Share by Region (2015-2020)
Table 11. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Biologics and Biosimilars Revenue Share by Region (2015-2020)
Table 13. Global Biologics and Biosimilars Sales (K Units) Forecast by Region (2021-2026)
Table 14. Global Biologics and Biosimilars Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Biologics and Biosimilars Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Biologics and Biosimilars Revenue Share Forecast by Region (2021-2026)
Table 17. Global Biologics and Biosimilars (K Units) of Key Companies (2015-2020)
Table 18. Global Biologics and Biosimilars Sales Share by Company (2015-2020)
Table 19. Global Biologics and Biosimilars Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Biologics and Biosimilars Revenue Share by Company (2015-2020)
Table 21. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biologics and Biosimilars as of 2019)
Table 22. Global Biologics and Biosimilars Average Price (USD/Unit) of Key Company (2015-2020)
Table 23. Manufacturers Biologics and Biosimilars Manufacturing Sites and Area Served
Table 24. Manufacturers Biologics and Biosimilars Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Biologics and Biosimilars Players
Table 27. Global Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 28. Global Biologics and Biosimilars Sales Share by Type (2015-2020)
Table 29. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Biologics and Biosimilars Price (K Units) by Type (2015-2020)
Table 31. Global Biologics and Biosimilars Sales Share by Type (2021-2026)
Table 32. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Biologics and Biosimilars Revenue Share by Type (2021-2026)
Table 34. Global Biologics and Biosimilars Price (K Units) by Type (2021-2026)
Table 35. Global Biologics and Biosimilars Sales (K Units) by Application (2015-2020)
Table 36. Global Biologics and Biosimilars Sales Share by Application (2015-2020)
Table 37. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Biologics and Biosimilars Price (K Units) by Application (2015-2020)
Table 39. Global Biologics and Biosimilars Sales (K Units) by Application (2021-2026)
Table 40. Global Biologics and Biosimilars Sales Share by Application (2021-2026)
Table 41. Global Biologics and Biosimilars Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Biologics and Biosimilars Revenue Share by Application (2021-2026)
Table 43. Global Biologics and Biosimilars Price (K Units) by Application (2021-2026)
Table 44. United States Biologics and Biosimilars Sales (K Units) by Company (2015-2020)
Table 45. United States Biologics and Biosimilars Sales Market Share by Company (2015-2020)
Table 46. United States Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 47. United States Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 48. United States Biologics and Biosimilars Sales (K Units) by Application (2015-2020)
Table 49. United States Biologics and Biosimilars Sales Market Share by Application (2015-2020)
Table 50. Europe Biologics and Biosimilars Sales (K Units) by Company (2015-2020)
Table 51. Europe Biologics and Biosimilars Sales Market Share by Company (2015-2020)
Table 52. Europe Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 53. Europe Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 54. Europe Biologics and Biosimilars Sales (K Units) by Application (2015-2020)
Table 55. Europe Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 56. China Biologics and Biosimilars Sales (K Units) by Company (2015-2020)
Table 57. China Biologics and Biosimilars Sales Market Share by Company (2015-2020)
Table 58. China Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 59. China Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 60. China Biologics and Biosimilars Sales (K Units) by Application (2015-2020)
Table 61. China Biologics and Biosimilars Sales Market Share by Application (2015-2020)
Table 62. Japan Biologics and Biosimilars Sales (K Units) by Company (2015-2020)
Table 63. Japan Biologics and Biosimilars Sales Market Share by Company (2015-2020)
Table 64. Japan Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 65. Japan Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 66. Japan Biologics and Biosimilars Sales (K Units) by Application (2015-2020)
Table 67. Japan Biologics and Biosimilars Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Biologics and Biosimilars Sales (K Units) by Company (2015-2020)
Table 69. Southeast Asia Biologics and Biosimilars Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 71. Southeast Asia Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 73. Southeast Asia Biologics and Biosimilars Sales Market Share by Application (2015-2020)
Table 74. India Biologics and Biosimilars Sales (K Units) by Company (2015-2020)
Table 75. India Biologics and Biosimilars Sales Market Share by Company (2015-2020)
Table 76. India Biologics and Biosimilars Sales (K Units) by Type (2015-2020)
Table 77. India Biologics and Biosimilars Sales Market Share by Type (2015-2020)
Table 78. India Biologics and Biosimilars Sales (K Units) by Application (2015-2020)
Table 79. India Biologics and Biosimilars Sales Market Share by Application (2015-2020)
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. Roche Biologics and Biosimilars Product
Table 84. Roche Recent Development
Table 85. Amgen Corporation Information
Table 86. Amgen Description and Business Overview
Table 87. Amgen Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Amgen Biologics and Biosimilars Product
Table 89. Amgen Recent Development
Table 90. AbbVie Corporation Information
Table 91. AbbVie Description and Business Overview
Table 92. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. AbbVie Biologics and Biosimilars Product
Table 94. AbbVie Recent Development
Table 95. Sanofi-Aventis Corporation Information
Table 96. Sanofi-Aventis Description and Business Overview
Table 97. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Sanofi-Aventis Biologics and Biosimilars Product
Table 99. Sanofi-Aventis Recent Development
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Business Overview
Table 102. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Johnson & Johnson Biologics and Biosimilars Product
Table 104. Johnson & Johnson Recent Development
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Pfizer Biologics and Biosimilars Product
Table 109. Pfizer Recent Development
Table 110. Novo Nordisk Corporation Information
Table 111. Novo Nordisk Description and Business Overview
Table 112. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Novo Nordisk Biologics and Biosimilars Product
Table 114. Novo Nordisk Recent Development
Table 115. Eli Lilly Corporation Information
Table 116. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 117. Eli Lilly Description and Business Overview
Table 118. Eli Lilly Biologics and Biosimilars Product
Table 119. Eli Lilly Recent Development
Table 120. Novartis Corporation Information
Table 121. Novartis Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 122. Novartis Description and Business Overview
Table 123. Novartis Biologics and Biosimilars Product
Table 124. Novartis Recent Development
Table 125. Merck Corporation Information
Table 126. Merck Description and Business Overview
Table 127. Merck Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Merck Biologics and Biosimilars Product
Table 129. Merck Recent Development
Table 130. 3sbio Corporation Information
Table 131. 3sbio Description and Business Overview
Table 132. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 133. 3sbio Biologics and Biosimilars Product
Table 134. 3sbio Recent Development
Table 135. Changchun High Tech Corporation Information
Table 136. Changchun High Tech Description and Business Overview
Table 137. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 138. Changchun High Tech Biologics and Biosimilars Product
Table 139. Changchun High Tech Recent Development
Table 140. CP Guojian Corporation Information
Table 141. CP Guojian Description and Business Overview
Table 142. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 143. CP Guojian Biologics and Biosimilars Product
Table 144. CP Guojian Recent Development
Table 145. Biotech Corporation Information
Table 146. Biotech Description and Business Overview
Table 147. Biotech Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 148. Biotech Biologics and Biosimilars Product
Table 149. Biotech Recent Development
Table 150. Gelgen Corporation Information
Table 151. Gelgen Description and Business Overview
Table 152. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 153. Gelgen Biologics and Biosimilars Product
Table 154. Gelgen Recent Development
Table 155. Innovent Corporation Information
Table 156. Innovent Description and Business Overview
Table 157. Innovent Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 158. Innovent Biologics and Biosimilars Product
Table 159. Innovent Recent Development
Table 160. Dong Bao Corporation Information
Table 161. Dong Bao Description and Business Overview
Table 162. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table 163. Dong Bao Biologics and Biosimilars Product
Table 164. Dong Bao Recent Development
Table . Ganlee Corporation Information
Table . Ganlee Description and Business Overview
Table . Ganlee Biologics and Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2015-2020)
Table . Ganlee Biologics and Biosimilars Product
Table . Ganlee Recent Development
Table 170. Production Base and Market Concentration Rate of Raw Material
Table 171. Key Suppliers of Raw Materials
Table 172. Biologics and Biosimilars Distributors List
Table 173. Biologics and Biosimilars Customers List
Table 174. Market Key Trends
Table 175. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 176. Key Challenges
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Biologics and Biosimilars Market Share by Application in 2020 & 2026
Figure 6. Tumor Examples
Figure 7. Diabetes Examples
Figure 8. Cardiovascular Examples
Figure 9. Hemophilia Examples
Figure 10. Other Examples
Figure 11. Global Biologics and Biosimilars Sales (K Units) Growth Rate (2015-2026)
Figure 12. Global Biologics and Biosimilars Revenue (US$ Million) Growth Rate (2015-2026)
Figure 13. Global Biologics and Biosimilars Price Trends Growth Rate (2015-2026) (USD/Unit)
Figure 14. Global Biologics and Biosimilars Revenue Market Share by Region: 2015 VS 2020
Figure 15. Global Biologics and Biosimilars Revenue Market Share by Region: 2021 VS 2026
Figure 16. United States Biologics and Biosimilars Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. United States Biologics and Biosimilars Sales (K Units) Growth Rate (2015-2026)
Figure 18. Europe Biologics and Biosimilars Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. Europe Biologics and Biosimilars Sales (Million USD) Growth Rate (2015-2026)
Figure 20. China Biologics and Biosimilars Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. China Biologics and Biosimilars Sales (Million USD) and Growth Rate (2015-2026)
Figure 22. Japan Biologics and Biosimilars Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Japan Biologics and Biosimilars Sales (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Biologics and Biosimilars Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. Southeast Asia Biologics and Biosimilars Sales (Million USD) Growth Rate (2015-2026)
Figure 26. India Biologics and Biosimilars Revenue (Million USD) Growth Rate (2015-2026)
Figure 27. India Biologics and Biosimilars Sales (Million USD) Growth Rate (2015-2026)
Figure 28. Global 5 Largest Biologics and Biosimilars Players Market Share by Revenue in Biologics and Biosimilars 2015 & 2019
Figure 29. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 30. Global Biologics and Biosimilars Revenue Share by Type (2015-2020)
Figure 31. Global Biologics and Biosimilars Revenue Growth Rate by Type in 2015 & 2019
Figure 32. Global Biologics and Biosimilars Revenue Share by Application (2015-2020)
Figure 33. Global Biologics and Biosimilars Revenue Growth Rate by Application in 2015 & 2019
Figure 34. United States Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 35. United States Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 36. Europe Biologics and Biosimilars Sales Market Share by Company in 2019
Figure 37. Europe Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 38. Europe Biologics and Biosimilars Sales Market Share by Application in 2019
Figure 39. China Biologics and Biosimilars Sales Market Share by Company in 2019
Figure 40. China Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 41. China Biologics and Biosimilars Sales Market Share by Application in 2019
Figure 42. Japan Biologics and Biosimilars Sales Market Share by Company in 2019
Figure 43. Japan Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 44. Japan Biologics and Biosimilars Sales Market Share by Application in 2019
Figure 45. Southeast Asia Biologics and Biosimilars Sales Market Share by Company in 2019
Figure 46. Southeast Asia Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 47. Southeast Asia Biologics and Biosimilars Sales Market Share by Application in 2019
Figure 48. India Biologics and Biosimilars Sales Market Share by Company in 2019
Figure 49. India Biologics and Biosimilars Sales Market Share by Type in 2019
Figure 50. India Biologics and Biosimilars Sales Market Share by Application in 2019
Figure 51. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Sanofi-Aventis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. 3sbio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Changchun High Tech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. CP Guojian Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Biotech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Gelgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Innovent Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Dong Bao Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Ganlee Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Key Raw Materials Price Trend
Figure 70. Manufacturing Cost Structure of Biologics and Biosimilars
Figure 71. Manufacturing Process Analysis of Biologics and Biosimilars
Figure 72. Biologics and Biosimilars Industrial Chain Analysis
Figure 73. Channels of Distribution
Figure 74. Distributors Profiles
Figure 75. Porter's Five Forces Analysis
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
生物製剤及びバイオシミラーの世界市場 2020年：メーカー別、地域別、種類・用途別 Summary Market Overview The global Biologics and Biosimilars market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.3% in the forecast period of 2020 to 2025 and will expected to reach USD 279640 million by 2025, from USD 236240 million in 2019. The Bi…- バイオシミラー/バイオ後続品の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Biosimilars/Follow-on-Biologics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Biosimilars/F…
- ヘレセプチンバイオシミラーの世界市場レポート2020 Herceptin, also known as trastuzumab, is used as a medication for patients who suffer from cancer, which assists in controlling the growth and spread of cancer cells in the body. Herceptin biosimilars are essentially used to treat certain breast as well stomach cancers, and is also used in combinati…
- バイオシミラーの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Biosimilars market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 17.2% in the forecast period of 2020 to 2025 and will expected to reach USD 9643.4 million by 2025, from USD 5111 million in 2019. The Biosimilars market report…
- バイオ医薬品Cmo＆Croの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Biopharmaceutical Cmo & Cro market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Biopharmaceutical…